(R)-[11C]Verapamil PET studies to assess changes in P-glycoprotein expression and functionality in rat blood-brain barrier after exposure to kainate-induced status epilepticus

BMC Medical Imaging

Volumn 11, Issue , 2011, Pages

  Syvänen, Stina ^a   Luurtsema, Gert ^b   Molthoff, Carla F M ^c   Windhorst, Albert D ^c   Huisman, Marc C ^c   Lammertsma, Adriaan A ^c   Voskuyl, Rob A ^a,d   de Lange, Elizabeth C ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d STICHTING EPILEPSIE INSTELLINGEN NEDERLAND SEIN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CARBON; DIAGNOSTIC AGENT; GLYCOPROTEIN P; KAINIC ACID; RADIOPHARMACEUTICAL AGENT; VERAPAMIL;

ANIMAL; ARTICLE; BLOOD BRAIN BARRIER; CHEMICALLY INDUCED DISORDER; EPILEPTIC STATE; MALE; METABOLISM; METHODOLOGY; POSITRON EMISSION TOMOGRAPHY; RAT; SCINTISCANNING; SPRAGUE DAWLEY RAT; TISSUE DISTRIBUTION;

ANIMALS; BLOOD-BRAIN BARRIER; CALCIUM CHANNEL BLOCKERS; CARBON RADIOISOTOPES; KAINIC ACID; MALE; P-GLYCOPROTEIN; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RATS; RATS, SPRAGUE-DAWLEY; STATUS EPILEPTICUS; TISSUE DISTRIBUTION; VERAPAMIL;

EID: 78650752621     PISSN: None     EISSN: 14712342     Source Type: Journal    
DOI: 10.1186/1471-2342-11-1     Document Type: Article

References (58)

1. Schmidt D, Löscher W. Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms. Epilepsia 2005, 46(6):858-877. 10.1111/j.1528-1167.2005.54904.x, 15946327.
2. Regesta G, Tanganelli P. Clinical aspects and biological bases of drug-resistant epilepsies. Epilepsy Res 1999, 34(2-3):109-122. 10.1016/S0920-1211(98)00106-5, 10210025.
3. Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR, Bertino JR. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 1989, 86(2):695-698. 10.1073/pnas.86.2.695, 286540, 2563168.
4. Schinkel AH, Jonker JW. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 2003, 55(1):3-29. 10.1016/S0169-409X(02)00169-2, 12535572.
5. Brandt C, Bethmann K, Gastens AM, Loscher W. The multidrug transporter hypothesis of drug resistance in epilepsy: Proof-of-principle in a rat model of temporal lobe epilepsy. Neurobiol Dis 2006, 24(1):202-211. 10.1016/j.nbd.2006.06.014, 16928449.
6. van Vliet EA, Zibell G, Pekcec A, Schlichtiger J, Edelbroek PM, Holtman L, Aronica E, Gorter JA, Potschka H. COX-2 inhibition controls P-glycoprotein expression and promotes brain delivery of phenytoin in chronic epileptic rats. Neuropharmacology 2009, 58(2):404-412. 10.1016/j.neuropharm.2009.09.012, 19786037.
7. Rizzi M, Caccia S, Guiso G, Richichi C, Gorter JA, Aronica E, Aliprandi M, Bagnati R, Fanelli R, D'Incalci M, et al. Limbic seizures induce P-glycoprotein in rodent brain: functional implications for pharmacoresistance. J Neurosci 2002, 22(14):5833-5839.
8. Hocht C, Lazarowski A, Gonzalez NN, Auzmendi J, Opezzo JA, Bramuglia GF, Taira CA, Girardi E. Nimodipine restores the altered hippocampal phenytoin pharmacokinetics in a refractory epileptic model. Neurosci Lett 2007, 413(2):168-172. Epub 2007 Jan 2008, 10.1016/j.neulet.2006.11.075, 17240061.
9. Hocht C, Lazarowski A, Gonzalez NN, Mayer MA, Opezzo JA, Taira CA, Girardi E. Differential hippocampal pharmacokinetics of phenobarbital and carbamazepine in repetitive seizures induced by 3-mercaptopropionic acid. Neurosci Lett 2009, 453(1):54-57. Epub 2009 Feb 2004, 10.1016/j.neulet.2009.01.079, 19429015.
10. Sisodiya SM, Lin WR, Harding BN, Squier MV, Thom M. Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy. Brain 2002, 125(Pt 1):22-31. 10.1093/brain/awf002, 11834590.
11. Tishler DM, Weinberg KI, Hinton DR, Barbaro N, Annett GM, Raffel C. MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia 1995, 36(1):1-6. 10.1111/j.1528-1157.1995.tb01657.x, 8001500.
12. Dombrowski SM, Desai SY, Marroni M, Cucullo L, Goodrich K, Bingaman W, Mayberg MR, Bengez L, Janigro D. Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy. Epilepsia 2001, 42(12):1501-1506. 10.1046/j.1528-1157.2001.12301.x, 11879359.
13. van Vliet EA, van Schaik R, Edelbroek PM, Redeker S, Aronica E, Wadman WJ, Marchi N, Vezzani A, Gorter JA. Inhibition of the multidrug transporter P-glycoprotein improves seizure control in phenytoin-treated chronic epileptic rats. Epilepsia 2006, 47(4):672-680. 10.1111/j.1528-1167.2006.00496.x, 16650133.
14. Löscher W, Potschka H. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog Neurobiol 2005, 76(1):22-76.
15. Luna-Tortos C, Rambeck B, Jurgens UH, Loscher W. The Antiepileptic Drug Topiramate is a Substrate for Human P-glycoprotein but Not Multidrug Resistance Proteins. Pharm Res 2009, 3:3.
16. Sisodiya SM, Heffernan J, Squier MV. Over-expression of P-glycoprotein in malformations of cortical development. Neuroreport 1999, 10(16):3437-3441. 10.1097/00001756-199911080-00032, 10599858.
17. Löscher W, Potschka H. Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. J Pharmacol Exp Ther 2002, 301(1):7-14.
18. Robey RW, Lazarowski A, Bates SE. P-glycoprotein--a clinical target in drug-refractory epilepsy?. Mol Pharmacol 2008, 73(5):1343-1346. 10.1124/mol.108.046680, 18314494.
19. Pekcec A, Unkruer B, Stein V, Bankstahl JP, Soerensen J, Tipold A, Baumgartner W, Potschka H. Over-expression of P-glycoprotein in the canine brain following spontaneous status epilepticus. Epilepsy Res 2009, 83(2-3):144-151. 10.1016/j.eplepsyres.2008.10.010, 19059762.
20. Bankstahl JP, Löscher W. Resistance to antiepileptic drugs and expression of P-glycoprotein in two rat models of status epilepticus. Epilepsy Res 2008, 82(1):70-85. 10.1016/j.eplepsyres.2008.07.007, 18760905.
21. Löscher W. How to explain multidrug resistance in epilepsy?. Epilepsy Curr 2005, 5:107-112. 1198632, 16145617.
22. Anderson GD, Shen DD. Where is the evidence that p-glycoprotein limits brain uptake of antiepileptic drug and contributes to drug resistance in epilepsy?. Epilepsia 2007, 48(12):2372-2374. 10.1111/j.1528-1167.2007.01260_3.x, 18088270.
23. Hellier JL, Patrylo PR, Buckmaster PS, Dudek FE. Recurrent spontaneous motor seizures after repeated low-dose systemic treatment with kainate: assessment of a rat model of temporal lobe epilepsy. Epilepsy Res 1998, 31(1):73-84. 10.1016/S0920-1211(98)00017-5, 9696302.
24. van Vliet E, Aronica E, Redeker S, Marchi N, Rizzi M, Vezzani A, Gorter J. Selective and persistent upregulation of mdr1b mRNA and P-glycoprotein in the parahippocampal cortex of chronic epileptic rats. Epilepsy Res 2004, 60(2-3):203-213. 10.1016/j.eplepsyres.2004.06.005, 15380564.
25. Bart J, Willemsen AT, Groen HJ, van der Graaf WT, Wegman TD, Vaalburg W, de Vries EG, Hendrikse NH. Quantitative assessment of P-glycoprotein function in the rat blood-brain barrier by distribution volume of [11C]verapamil measured with PET. Neuroimage 2003, 20(3):1775-1782. 10.1016/S1053-8119(03)00405-1, 14642487.
26. Bankstahl JP, Kuntner C, Abrahim A, Karch R, Stanek J, Wanek T, Wadsak W, Kletter K, Muller M, Löscher W, et al. Tariquidar-induced P-glycoprotein inhibition at the rat blood-brain barrier studied with (R)-11C-verapamil and PET. J Nucl Med 2008, 49(8):1328-1335. 10.2967/jnumed.108.051235, 18632828.
27. Hendrikse NH, de Vries EG, Eriks-Fluks L, van der Graaf WT, Hospers GA, Willemsen AT, Vaalburg W, Franssen EJ. A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier. Cancer Res 1999, 59(10):2411-2416.
28. Syvänen S, Blomquist G, Sprycha M, Höglund AU, Roman M, Eriksson O, Hammarlund-Udenaes M, Långström B, Bergström M. Duration and degree of cyclosporin induced P-glycoprotein inhibition in the rat blood-brain barrier can be studied with PET. Neuroimage 2006, 32(3):1134-1141.
29. Sasongko L, Link JM, Muzi M, Mankoff DA, Yang X, Collier AC, Shoner SC, Unadkat JD. Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography. Clin Pharmacol Ther 2005, 77(6):503-514. 10.1016/j.clpt.2005.01.022, 15961982.
30. Lee YJ, Maeda J, Kusuhara H, Okauchi T, Inaji M, Nagai Y, Obayashi S, Nakao R, Suzuki K, Sugiyama Y, et al. In vivo evaluation of P-glycoprotein function at the blood-brain barrier in nonhuman primates using [11C]verapamil. J Pharmacol Exp Ther 2006, 316(2):647-653. 10.1124/jpet.105.088328, 16293715.
31. Toornvliet R, van Berckel BN, Luurtsema G, Lubberink M, Geldof AA, Bosch TM, Oerlemans R, Lammertsma AA, Franssen EJ. Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-[(11)C]verapamil and positron emission tomography. Clin Pharmacol Ther 2006, 79(6):540-548. 10.1016/j.clpt.2006.02.004, 16765142.
32. Ikoma Y, Takano A, Ito H, Kusuhara H, Sugiyama Y, Arakawa R, Fukumura T, Nakao R, Suzuki K, Suhara T. Quantitative analysis of 11C-verapamil transfer at the human blood-brain barrier for evaluation of P-glycoprotein function. J Nucl Med 2006, 47(9):1531-1537.
33. Kortekaas R, Leenders KL, van Oostrom JC, Vaalburg W, Bart J, Willemsen AT, Hendrikse NH. Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol 2005, 57(2):176-179. 10.1002/ana.20369, 15668963.
34. Langer O, Bauer M, Hammers A, Karch R, Pataraia E, Koepp MJ, Abrahim A, Luurtsema G, Brunner M, Sunder-Plassmann R, et al. Pharmacoresistance in epilepsy: a pilot PET study with the P-glycoprotein substrate R-[(11)C]verapamil. Epilepsia 2007, 48(9):1774-1784. 10.1111/j.1528-1167.2007.01116.x, 17484754.
35. Racine R, Okujava V, Chipashvili S. Modification of seizure activity by electrical stimulation. 3. Mechanisms. Electroencephalogr Clin Neurophysiol 1972, 32(3):295-299. 10.1016/0013-4694(72)90178-2, 4110398.
36. Luurtsema G, Windhorst AD, J MP, Herscheid JDM, Lammertsma AA, Franssen EJ. Fully automated high yield synthesis of (R)- and (S)-[11C]verapamil for measuring the P-glycoprotein function with positron emission tomography. J Labelled Compd Radiopharm 2002, 45:1199-1207.
37. de Jong HW, van Velden FH, Kloet RW, Buijs FL, Boellaard R, Lammertsma AA. Performance evaluation of the ECAT HRRT: an LSO-LYSO double layer high resolution, high sensitivity scanner. Phys Med Biol 2007, 52(5):1505-1526. 10.1088/0031-9155/52/5/019, 17301468.
38. van Velden FH, Kloet RW, van Berckel BN, Molthoff CF, de Jong HW, Lammertsma AA, Boellaard R. Impact of attenuation correction strategies on the quantification of High Resolution Research Tomograph PET studies. Phys Med Biol 2008, 53(1):99-118. 10.1088/0031-9155/53/1/007, 18182690.
39. van Velden FH, Kloet RW, van Berckel BN, Buijs FL, Luurtsema G, Lammertsma AA, Boellaard R. HRRT Versus HR+ Human Brain PET Studies: An Interscanner Test-Retest Study. J Nucl Med 2009, 50(5):693-702. 10.2967/jnumed.108.058628, 19372482.
40. Luurtsema G, Molthoff CF, Schuit RC, Windhorst AD, Lammertsma AA, Franssen EJ. Evaluation of (R)-[11C]verapamil as PET tracer of P-glycoprotein function in the blood-brain barrier: kinetics and metabolism in the rat. Nucl Med Biol 2005, 32(1):87-93. 10.1016/j.nucmedbio.2004.06.007, 15691665.
41. Volk H, Potschka H, Loscher W. Immunohistochemical localization of P-glycoprotein in rat brain and detection of its increased expression by seizures are sensitive to fixation and staining variables. J Histochem Cytochem 2005, 53(4):517-531. 10.1369/jhc.4A6451.2005, 15805426.
42. Paxinos G, Watson C. The Rat Brain in stereotaxic coordinates. 1986, New York: Academic Press, 2.
43. Abramoff MD, Magelhaes PJ, Ram SJ. Image Processing with ImageJ. Biophotonics International 2004, 11(7):36-42.
44. Loening AM, Gambhir SS. AMIDE: A free software tool for multimodality medical image analysis. Mol Imaging 2003, 2:131-137. 10.1162/153535003322556877, 14649056.
45. Todd MM, Weeks JB, Warner DS. Cerebral blood flow, blood volume, and brain tissue hematocrit during isovolemic hemodilution with hetastarch in rats. Am J Physiol 1992, 263(1 Pt 2):H75-82.
46. Lubberink M, Luurtsema G, van Berckel BN, Boellaard R, Toornvliet R, Windhorst AD, Franssen EJ, Lammertsma AA. Evaluation of tracer kinetic models for quantification of P-glycoprotein function using (R)-[11C]verapamil and PET. J Cereb Blood Flow Metab 2007, 27(2):424-433. 10.1038/sj.jcbfm.9600349, 16757979.
47. Logan J, Fowler JS, Volkow ND, Wolf AP, Dewey SL, Schlyer DJ, MacGregor RR, Hitzemann R, Bendriem B, Gatley SJ, et al. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab 1990, 10(5):740-747.
48. Gunn RN, Gunn SR, Cunningham VJ. Positron emission tomography compartmental models. J Cereb Blood Flow Metab 2001, 21(6):635-652. 10.1097/00004647-200106000-00002, 11488533.
49. Akaike H. A new look at the statistical model identification. IEEE Trans Autom Control 1974, 19:716-723.
50. Jonsson EN, Karlsson MO. Xpose - an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Computer Methods and Programs in Biomedicine 1999, 58(1):51-64. 10.1016/S0169-2607(98)00067-4, 10195646.
51. Wilkins JJ. NONMEMory: a run management tool for NONMEM. Comput Methods Programs Biomed 2005, 78(3):259-267. 10.1016/j.cmpb.2005.02.003, 15899310.
52. Zibell G, Unkruer B, Pekcec A, Hartz AM, Bauer B, Miller DS, Potschka H. Prevention of seizure-induced up-regulation of endothelial P-glycoprotein by COX-2 inhibition. Neuropharmacology 2009, 56(5):849-855. 10.1016/j.neuropharm.2009.01.009, 19371577.
53. Potschka H. Targeting regulation of ABC efflux transporters in brain diseases: a novel therapeutic approach. Pharmacol Ther 2009, 125(1):118-127. 10.1016/j.pharmthera.2009.10.004, 19896502.
54. Henry TR, Votaw JR. The role of positron emission tomography with [18F]fluorodeoxyglucose in the evaluation of the epilepsies. Neuroimaging Clin N Am 2004, 14(3):517-535. ix, 10.1016/j.nic.2004.04.011, 15324862.
55. Syvänen S, Hooker A, Rahman O, Wilking H, Blomquist G, Långström B, Bergström M, Hammarlund-Udenaes M. Pharmacokinetics of P-glycoprotein inhibition in the rat blood-brain barrier. J Pharm Sci 2008, 97(12):5386-5400.
56. Ronaldson PT, Persidsky Y, Bendayan R. Regulation of ABC membrane transporters in glial cells: relevance to the pharmacotherapy of brain HIV-1 infection. Glia 2008, 56(16):1711-1735. 10.1002/glia.20725, 18649402.
57. Lazarova N, Zoghbi SS, Hong J, Seneca N, Tuan E, Gladding RL, Liow JS, Taku A, Innis RB, Pike VW. Synthesis and evaluation of [N-methyl-11C]N-desmethyl-loperamide as a new and improved PET radiotracer for imaging P-gp function. J Med Chem 2008, 51(19):6034-6043. 10.1021/jm800510m, 2646255, 18783208.
58. Bartmann H, Fuest C, La Fougere C, Xiong G, Just T, Schlichtiger J, Winter P, Boning G, Wangler B, Pekcec A, et al. Imaging of P-glycoprotein-mediated pharmacoresistance in the hippocampus: Proof-of-concept in a chronic rat model of temporal lobe epilepsy. Epilepsia 2010, 51(9):1780-1790. 10.1111/j.1528-1167.2010.02671.x, 20633036.